Login / Register The Most Trusted Name in Medical Education

Cardiology

Look no further for the most cutting edge cardiology CME courses. We offer cardiology continuing medical education courses in dyslipidemia, acute coronary syndrome (acs), and Morquio A Syndrome, among others.

Elsevier LSD Exchange 2018 02 Web 116x140

THE LSD EXCHANGE: OPTIMIZING DIAGNOSIS AND FUTURE MANAGMENT

Format: Live Symposium

This symposium will bring together experts from around the world to engage in a lively in-depth discussion on the key clinical questions and controversies in the diagnosis of lysosomal storage diseases (LSDs) and the future direction of LSD management. This program will address the consequences of delayed diagnosis and treatment initiation, and help you better understand diagnostic options. The experts will discuss genotype–phenotype correlations and their significance for daily clinical practice, and provide perspectives on emerging therapeutic developments and strategies for the treatment of LSDs.  

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
AHA E 116 x 140

APPLYING PCSK9 INHIBITORS TO OPTIMIZE OUTCOMES IN PATIENTS WITH DYSLIPIDEMIA

Format: Webcast

The content for this activity is derived from a live symposium titled, “Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetic patient subset. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly in the high-risk population. Dr. Christopher P. Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia.

Take Course »

 

 

Credits: 1.50 AMA PRA Category 1 Credit(s)™
910755 116 x 120

AHA 2017: APPLYING PCSK9 INHIBITORS TO IMPROVE OUTCOMES AND THE OVERALL QUALITY OF LIFE FOR PATIENTS WITH DYSLIPIDEMIA

Format: Conference Reporter

This Elsevier Conference Reporter will cover data presented at the American Heart Association (AHA) Scientific Session 2017 held in Anaheim, CA. The expert faculty will discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia including achieving LDL-C goals, cardiovascular risk reduction and managing special patient populations. Current and emerging clinical trial data of PCSK9 inhibitors will be analyzed. The faculty will discuss different approaches of how to implement newer therapies into individualized treatment plans. Upon completing this activity, clinicians will gain a better understanding of treatment options to provide better outcomes for patients with dyslipidemia.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910702 E 116 x 140

Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of PCSK9 Inhibitor Therapeutics

Format: Webcast

This educational content was derived from the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.

Take Course »

Credits: 2.00 AMA PRA Category 1 Credit(s)™
910748 116 x 140

THE ROLE OF PCSK9 INHIBITORS IN LOWERING LDL-C AND REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIA

Format: Conference Reporter

This CME program will feature content presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. Four expert faculty will analyze recent therapeutic advances in the treatment and management of patients with dylispidemia, as well as the role of PCSK9 inhibitors in lowering LDL-C and reducing cardiovascular risk in those patients. Long-term cardiovascular efficacy and safety data will be reviewed, and clinical relevance debated. Further, the expert faculty will outline strategies for utilizing the inter-professional team and incorporating recent data into individualized treatment plans. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of dyslipidemia as it relates to improving outcomes and quality of life in clinical practice.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910732 116 x 140 2

STRENGTH IN NUMBERS: A TEAM-BASED APPROACH TO MANAGING PATIENTS WITH HYPONATREMIA

Format: Webcast

These virtual patient panels provide learners with real-world application of best practices among various members of the healthcare team in the management of patients with hyponatremia. A patient case is provided, followed by discussion among the team members to provide insight and context to why particular courses of action were chosen.

Take Course »

 

Credits: Up to 1.00 AMA PRA Category 1 Credit(s)™
910746 116 x 140

AN UPDATE ON EMERGING S1P THERAPEUTICS FOR THE MANAGEMENT OF PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

Format: Conference Reporter

This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910710 116 x 140

ACC 2017: A Therapeutic Update to Reduce Risk and Optimize Outcomes for Patients with Reduced or Preserved Ejection Fraction Heart Failure

Format: Webcast

 

This Official Elsevier Clinical Perspectives and Analysis will cover data presented at the American College of Cardiology 66th Annual Scientific Sessions and Expo held in Washington, DC. The four expert faculty will discuss the most up to date statistics and therapeutic advances for patients with preserved ejection fraction heart failure. The faculty will debate measures of prognosis and biomarkers to enhance treatment plans. Current clinical trial data will be examined in cross reference with new and emerging combination therapies to better serve patients. Upon completion of this activity physicians will gain a better understanding of treatment options to provide better outcomes for patients with ejection fraction heart failure.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
107 116 x 140

Achieving LDL-C Goal for all Patients in the Era of PCSK9 Inhibitors

Format: Webcast

This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.

Take Course »

Credits: 2.00 AMA PRA Category 1 Credit(s)™